Sender Herschorn

Efficacy and Safety of OnabotulinumtoxinA in Patients with Urinary Incontinence Due to Neurogenic Detrusor Overactivity: A Randomised, Double-Blind, Placebo-Controlled Trial

Francisco Cruz, Sender Herschorn, Philip J. Aliotta et al. · European Urology · 2011 · 471 citations

Medicine, Pharmacotherapy, Urology +16

Results of a Randomized Phase III Trial of Mirabegron in Patients with Overactive Bladder

Victor W. Νitti, Stephen M. Auerbach, Nancy Martin et al. · The Journal of Urology · 2012 · 368 citations

Medicine, Pharmacology, Pharmacotherapy +17

A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicentre Study to Assess the Efficacy and Safety of the β3 Adrenoceptor Agonist, Mirabegron, in Patients With Symptoms of Overactive Bladder

Sender Herschorn, Jack Barkin, David Castro‐Díaz et al. · Urology · 2013 · 246 citations

Medicine, Pharmacology, Pharmacotherapy +13

Incidence of complications other than urinary incontinence or erectile dysfunction after radical prostatectomy or radiotherapy for prostate cancer: a population-based cohort study

Robert K. Nam, Patrick Cheung, Sender Herschorn et al. · The Lancet Oncology · 2014 · 223 citations

Medicine, Surgery, Urology +17

Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE)

Marcus J. Drake, Christopher R. Chapple, Adil Esen et al. · European Urology · 2016 · 183 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17